Oncology PulsePoints: Metastatic CRPC ASCO Living Guidelines Updates

The 2024 ASCO living guideline update for metastatic castration-resistant prostate cancer (mCRPC) represents more than just the addition of new therapies—it marks a definitive shift toward biomarker-driven treatment sequencing. Vince Sung, PharmD, MBA, BCOP, BCPS, director of pharmacy in Oncology & Infusion at Ascension St. John in Tulsa, breaks down the three practice-changing phase 3 trials incorporated into the update, what they mean for clinical workflow, and why pharmacists are uniquely positioned to bridge the gap between guideline recommendations and real-world implementation.

Pharmacy Times: What are the most significant changes in the Update for Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, and how might they impact clinical practice?

Vince Sung, PharmD, MBA, BCOP, BCPS: The headline from this ASCO update is not just the addition of new therapies—it is a definitive shift toward biomarker-driven sequencing in treating metastatic CRPC. The guideline incorporates three practice-changing phase 3 trials: TALAPRO-2, PSMAfore, and PEACE-3, which together expand our therapeutic toolkit considerably.

First, there is now a much stronger recommendation for PARP inhibitor combinations in patients with HRR gene alterations, especially BRCA1 and BRCA2, thanks to updated survival data from TALAPRO-2 demonstrating an overall survival benefit. Talazoparib plus enzalutamide is now recommended alongside olaparib plus abiraterone and niraparib plus abiraterone as preferred treatment options for patients with mutated disease. The guideline also conditionally supports talazoparib plus enzalutamide in selected patients without HRR gene mutations.

Second, the guideline officially moves lutetium-177 PSMA upstream following the PSMAfore data. ASCO now recommends this radioligand therapy following progression on an ARPI, prior to docetaxel chemotherapy—and this is a massive paradigm shift in how we sequence these lines of treatment.

Third, the inclusion of enzalutamide plus radium-223 from the PEACE-3 trial is a major addition. Radium-223 has historically been a late-line option reserved for bone-predominant disease, but with demonstrated progression-free and overall survival benefit, this combination is now recommended earlier for patients without visceral metastasis.

Taken together, these three updates deliver a unifying message: comprehensive germline and somatic HRR testing is foundational for modern mCRPC care. Patients who are not profiled appropriately and in a timely manner risk being excluded from these clinically meaningful, life-extending therapies.

Pharmacy Times: From a pharmacy perspective, what unique considerations should clinicians be aware of when implementing this update, including operational and access challenges, toxicity management, and patient populations where this is especially relevant or potentially controversial?

Sung: From a pharmacy perspective, our considerations now begin with operationalizing early and consistent molecular testing. Because these guidelines lean heavily on germline and somatic testing, any delay in obtaining an HRR panel, MSI status, or PSMA imaging means a patient might miss the window for a highly effective targeted therapy.

Once those tests are back and treatment begins, the clinical focus shifts to managing increasingly complex and cumulative toxicity. Moving PARP inhibitor combinations earlier in the treatment course means we have to be incredibly proactive about tracking cytopenias and fatigue. These side effects typically surface a few months in, so upfront education and vigilant dose modification strategies are essential.

We also have to account for the significant operational shift happening with radioligand therapy. Implementing lutetium-177 PSMA requires a heavy lift that goes well beyond traditional medication management—it demands tight multidisciplinary coordination between nuclear medicine, radiation oncology, and pharmacy. And even with a more straightforward regimen like enzalutamide plus radium-223, pharmacists must champion mandatory supportive care, ensuring these patients are automatically started on a bone-protective agent to mitigate fracture risk.

Ultimately, because we now have so many excellent guideline-supported options—from PARP inhibitors and radioligand therapy to traditional docetaxel—the real challenge is sequencing. Pharmacists are uniquely equipped to look at the whole picture—cardiovascular history, underlying neuropathy, financial toxicity, and prior authorization status—to help the multidisciplinary team tailor the right sequence for the right patient.

Pharmacy Times: How do these updates align or conflict with what you're currently seeing in real-world practice?

Sung: Overall, this update aligns strongly with the direction advanced prostate cancer management has been heading at major academic centers. Comprehensive genomic testing is already becoming standard practice, and there is a clear consensus among practitioners that treatment selection must be biomarker-driven. The same is true for PSMA PET imaging — it is far more integrated into diagnostic and staging workflows than it was just a few years ago. In many ways, the guideline is validating what contemporary high-level practice already looks like.

Where we still see a gap is in implementation. Access to comprehensive genomic testing remains highly variable. It is not uncommon for a patient in a community setting to reach a later line of therapy without ever having a complete molecular profile—effectively excluding them from an early PARP inhibitor strategy. The same challenge exists with radioligand therapy. While the guideline appropriately positions lutetium-177 PSMA earlier in the treatment sequence, real-world availability remains dependent on institutional resources, nuclear medicine capacity, reimbursement pathways, and geographic access—meaning not every eligible patient has timely access to these treatments.

The guideline now also offers multiple evidence-based options for the same patient, which means sequencing decisions are increasingly individualized. The data tells us what can be done, but patient-specific factors dictate what should be done. Severe cardiovascular history may take certain options off the table entirely, and pre-existing neuropathy will prompt consideration of alternatives to taxane-based chemotherapy.

Ultimately, these updates are an accurate reflection of where the science is, while also providing a clear roadmap for where health systems and pharmacy teams need to improve.

Pharmacy Times: What is your key takeaway for pharmacists?

Sung: My key takeaway is that we need to view biomarker testing as an active therapeutic intervention — not just a diagnostic box to check. Historically, oncology pharmacists have focused on drug selection, toxicity management, and supportive care. While those roles remain vital, modern mCRPC management requires us to be just as proactive in identifying candidates for targeted therapies.

The effectiveness of PARP inhibitors and radioligand therapy hinges on timely biomarker identification. If testing is delayed or overlooked, patients lose access to potentially survival-extending options. As precision medicine continues to evolve, pharmacists are well positioned to bridge a critical gap — ensuring the right tests are ordered, results are acted upon, and access barriers are identified and addressed. Our role has expanded beyond medication management. We are now active contributors to the broader treatment strategy that guides each patient's care.

Let me know if you'd like to adjust the speaker's name/credentials once you have them, or if anything needs tightening up.